论文部分内容阅读
目的:探讨普米克令舒联合孟鲁司特治疗小儿慢性咳嗽的疗效。方法:选取我院门诊就诊的98例小儿慢性咳嗽患儿,随机分为观察组(普米克令舒+孟鲁司特)和对照组(普米克令舒)各49例。对比两组咳嗽频度评分、咳嗽严重度评分、咳嗽缓解时间、咳嗽消失时间、FEV1和PEF。结果:观察组总有效率87.76%显著高于对照组69.39%(P<0.05)。观察组咳嗽频度评分、咳嗽严重度评分、咳嗽缓解时间和咳嗽消失时间均显著短于对照组(P<0.05)。治疗前两组FEV1和PEF比较,差异无统计学意义(P>0.05)。治疗后两组FEV1和PEF均显著高于治疗前(P<0.05),且观察组FEV1和PEF均显著高于对照组(P<0.05)。结论:普米克令舒联合孟鲁司特治疗小儿慢性咳嗽的疗效显著,可以有效缓解患者临床症状,值得临床推广。
Objective: To investigate the curative effect of pulmicort and montelukast on children with chronic cough. Methods: A total of 98 pediatric patients with chronic cough from our outpatient clinic were randomly divided into observation group (pricketron and montelukast) and control group (pricketazone), 49 cases each. Cough frequency scores, cough severity scores, cough relief time, cough disappearance time, FEV1 and PEF were compared between the two groups. Results: The total effective rate in observation group was 87.76%, significantly higher than that in control group (69.39%, P <0.05). The cough frequency score, cough severity score, cough relieving time and cough disappearing time in the observation group were significantly shorter than those in the control group (P <0.05). There was no significant difference in FEV1 and PEF between the two groups before treatment (P> 0.05). After treatment, FEV1 and PEF in both groups were significantly higher than those before treatment (P <0.05), and FEV1 and PEF in the observation group were significantly higher than those in the control group (P <0.05). Conclusion: The combination of pulmicort and montelukast is effective in treating children with chronic cough, which can effectively relieve the clinical symptoms and is worthy of clinical promotion.